Sherwal Vinita, Malik Sonia, Bhatia Vandana
Department of Reproductive Medicine, Southend IVF and Fertility Centre, Holy Angeles Hospital, Community Centre, Basant Lok, Vasant Vihar, New Delhi, India.
J Hum Reprod Sci. 2010 May;3(2):85-90. doi: 10.4103/0974-1208.69342.
Ever since ovarian hyperstimulation syndrome (OHSS) was recognized as a clinical entity, various treatment modalities have been tried to prevent its occurrence and reduce its severity. Many recent studies have evaluated the role of dopamine agonists in reducing the incidence of OHSS.
To assess the effectiveness of dopamine agonist bromocriptine in reducing the incidence and severity of OHSS in patients undergoing assisted reproduction and its effect on pregnancy rates.
It was a prospective study in which patients at high risk of developing OHSS undergoing assisted reproduction were recruited.
The study was carried out from August 2008 to August 2009 in patients undergoing assisted reproduction and included 40 patients at high risk for developing OHSS. Tablet bromocriptine 2.5 mg was prescribed for a period of 16 days starting from day of ovum pick up. Patients were analyzed on the basis of incidence of moderate and severe OHSS, timing of onset of OHSS (early/late), hospitalization rate, pregnancy rates and tolerability of medication and were compared with a historical group of high responders matched for age and BMI.
Student's t test and proportion test were used.
There was a significant reduction in the incidence of moderate OHSS (P=0.037), early OHSS (P=0.012) as well as the number of admissions (P=0.030). Average duration of hospitalization was also significantly reduced (P=0.036). In the study group, the incidence of clinically significant OHSS was 17.5% as compared to 40.9% in the control group. No difference was detected between the groups in clinical pregnancy rates (P=0.0054).
Bromocriptine reduced the incidence and severity of clinically significant OHSS in high risk patients without affecting the pregnancy rates.
自从卵巢过度刺激综合征（OHSS）被确认为一种临床病症以来，人们尝试了各种治疗方法来预防其发生并减轻其严重程度。最近许多研究评估了多巴胺激动剂在降低OHSS发生率方面的作用。
评估多巴胺激动剂溴隐亭在降低接受辅助生殖患者OHSS发生率和严重程度方面的有效性及其对妊娠率的影响。
这是一项前瞻性研究，招募了有发生OHSS高风险且正在接受辅助生殖的患者。
该研究于2008年8月至2009年8月对接受辅助生殖的患者进行，纳入了40名有发生OHSS高风险的患者。从取卵日开始，给予溴隐亭片2.5毫克，服用16天。根据中度和重度OHSS的发生率、OHSS发作时间（早期/晚期）、住院率、妊娠率以及药物耐受性对患者进行分析，并与年龄和体重指数匹配的高反应者历史组进行比较。
采用学生t检验和比例检验。
中度OHSS的发生率（P = 0.037）、早期OHSS的发生率（P = 0.012）以及住院人数（P = 0.030）均有显著降低。平均住院时间也显著缩短（P = 0.036）。研究组中具有临床意义的OHSS发生率为17.5%，而对照组为40.9%。两组临床妊娠率无差异（P = 0.0054）。
溴隐亭降低了高风险患者中具有临床意义的OHSS的发生率和严重程度，且不影响妊娠率。
